What is the indication for Januvia (Sitagliptin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Januvia (sitagliptin) is indicated for the treatment of type 2 diabetes, with a typical dosage of 100 mg once daily, and may require dose adjustment in patients with kidney problems, as it has an intermediate glucose-lowering efficacy with a neutral effect on weight and no increased risk of hypoglycemia. The medication works by increasing the body's own insulin production and decreasing sugar production, helping to lower blood glucose levels. It's often used alone or in combination with other diabetes medications like metformin. Some key points to consider when prescribing Januvia include:

  • The most common side effects include upper respiratory tract infection, headache, and nasopharyngitis.
  • Patients should be aware of rare but serious side effects such as pancreatitis and report any severe abdominal pain to their doctor immediately.
  • Januvia is generally well-tolerated but may need dose adjustment in patients with kidney problems, as noted in the 2025 guidelines 1.
  • The medication doesn't cause weight gain or hypoglycemia when used alone, making it a favorable option for many patients.
  • Regular blood sugar monitoring and HbA1c tests are necessary to ensure the medication is working effectively, as recommended in the 2022 guidelines 1.
  • Patients should inform their healthcare provider of all other medications they're taking to avoid potential interactions, as outlined in the 2018 guidelines 1.
  • The dosage of Januvia may need to be adjusted based on kidney function, with a dose adjustment required for sitagliptin, saxagliptin, and alogliptin, as detailed in the 2012 guidelines 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Indication for Januvia (Sitagliptin)

The indication for Januvia (Sitagliptin) is for the treatment of type 2 diabetes mellitus. It can be used as monotherapy or in combination with other antidiabetic agents, such as metformin or a thiazolidinedione, to improve glycemic control in adult patients with type 2 diabetes 2, 3, 4, 5, 6.

Usage

Sitagliptin can be used:

  • As monotherapy to improve glycemic control in patients with type 2 diabetes 2, 3, 4, 5, 6
  • In combination with metformin or a thiazolidinedione (pioglitazone or rosiglitazone) when treatment with either drug alone provides inadequate glucose control 2
  • As an add-on agent to ongoing treatment with thiazolidinediones, sulfonylureas, or insulin with or without metformin, or metformin alone 3, 5

Dosage

The usual adult dose of sitagliptin is 100 mg once daily. A dose of 25-50 mg once daily is recommended for patients with moderate-to-severe renal impairment 2.

Benefits

Sitagliptin has several benefits, including:

  • Improving glycemic control in patients with type 2 diabetes 2, 3, 4, 5, 6
  • Having a low risk of hypoglycemia, except when used in combination with agents that may be associated with hypoglycemia, such as sulfonylureas or insulin 3, 5, 6
  • Being generally weight-neutral 3, 5, 6
  • Having a convenient once-daily oral regimen and low potential for pharmacokinetic drug-drug interactions 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.